Disease · MONDO_0004849

pulmonary emphysema

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pulmonary emphysema. Diseases, record MONDO_0004849. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004849

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pulmonary emphysema; Open Targets
Open Targets ID: MONDO_0004849; Open Targets
Other names: emphysema, emphysema, pulmonary; Open Targets
Disease Ontology: DOID:9675; Disease Ontology
MeSH: D004646; MeSH
MeSH: D011656; MeSH
NCI Thesaurus: C3348; NCI Thesaurus
Highest stage of its drugs: Approval, for 16 of its 37 drugs, from DailyMed, FDA, PMDA and TTD; Open Targets

Drugs37

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
.ALPHA.1-PROTEINASE INHIBITOR HUMAN	CHEMBL4297879	Protein	Approval	TTD	11	9	9	Drugs and targets
BUDESONIDE	CHEMBL1370	Small molecule	Approval	DailyMed and PMDA	4	2	2	Drugs and targets
FLUTICASONE PROPIONATE	CHEMBL1473	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
SALMETEROL XINAFOATE	CHEMBL1082607	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
TIOTROPIUM BROMIDE	CHEMBL3545181	Small molecule	Approval	DailyMed and PMDA	6	0	0	Drugs and targets
GLYCOPYRRONIUM BROMIDE	CHEMBL1201027	Small molecule	Approval	PMDA	4	0	0	Drugs and targets
UMECLIDINIUM BROMIDE	CHEMBL523299	Small molecule	Approval	DailyMed and PMDA	4	0	0	Drugs and targets
FORMOTEROL FUMARATE	CHEMBL3989798	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
FORMOTEROL FUMARATE HYDRATE	CHEMBL2133469	Small molecule	Approval	PMDA	3	0	0	Drugs and targets
INDACATEROL MALEATE	CHEMBL1789842	Small molecule	Approval	DailyMed and PMDA	3	0	0	Drugs and targets

1 to 10 of 37

See all 37 drugs

Targets23

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB2	Beta-2 adrenergic receptor	9	Beta-2 adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/154	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor M3	6	Muscarinic acetylcholine receptor M3 antagonist	Approval	https://conductscience.org/library/genes/1131	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Unknown	https://conductscience.org/library/genes/1441	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
RARG	Retinoic acid receptor	3	Retinoic acid receptor agonist; Retinoic acid receptor gamma agonist	Phase 2	https://conductscience.org/library/genes/5916	Drugs and targets
ELANE	Neutrophil elastase	2	Leukocyte elastase inhibitor	Approval	https://conductscience.org/library/genes/1991	Drugs and targets
PDE4A	Phosphodiesterase 4	2	Phosphodiesterase 4 inhibitor	Phase 3	https://conductscience.org/library/genes/5141	Drugs and targets
PDE4B	Phosphodiesterase 4	2	Phosphodiesterase 4 inhibitor	Phase 3	https://conductscience.org/library/genes/5142	Drugs and targets
PDE4C	Phosphodiesterase 4	2	Phosphodiesterase 4 inhibitor	Phase 3	https://conductscience.org/library/genes/5143	Drugs and targets
PDE4D	Phosphodiesterase 4	2	Phosphodiesterase 4 inhibitor	Phase 3	https://conductscience.org/library/genes/5144	Drugs and targets

1 to 10 of 23

See all 23 targets

Trials27

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02850978	Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease		1,335	2019-12-06	Pulmonary Disease, Chronic Obstructive	TIOTROPIUM	Its record names the disease	ClinicalTrials.gov
NCT00261833	Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency	Phase 4	180	2015-01-19	Alpha1-proteinase Inhibitor Deficiency, Emphysema	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Its record names the disease	ClinicalTrials.gov
NCT00670007	Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.	Phase 4	140	2016-07-12	Emphysema, Alpha 1-proteinase Inhibitor Deficiency	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Its record names the disease	ClinicalTrials.gov
NCT02006576	Prostaglandin Inhibition for Emphysema	Phase 2	118	2019-12-16	Emphysema	IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT00874497	Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema	Phase 2	84	2017-04-17	Chronic Obstructive Pulmonary Disease	TETOMILAST	Its record names the disease	ClinicalTrials.gov
NCT00263887	Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)	Phase 2	77	2014-08-21	Alpha 1-Antitrypsin Deficiency	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Its record names the disease	ClinicalTrials.gov
NCT01014442	A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients	Phase 3	68	2017-02-10	Lung Transplantation	MYCOPHENOLATE MOFETIL	Its record names the disease	ClinicalTrials.gov
NCT03679598	Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency	Phase 2	63	2024-07-09	Alpha-1 Antitrypsin Deficiency (AATD), PiZZ, PiSZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD	ALVELESTAT	Its record names the disease	ClinicalTrials.gov
NCT01744093	Doxycycline for COPD in HIV-Infected Patients	Not applicable	61	2018-10-10	HIV, Chronic Obstructive Pulmonary Disease (COPD), Emphysema	DOXYCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT02525861	GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study	Phase 3	34	2021-10-14	Alpha1-antitrypsin Deficiency	.ALPHA.1-PROTEINASE INHIBITOR HUMAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 27

See all 27 trials

Comparisons in its trials21

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Zemaira® vs Placebo: serious adverse events	28 of 93	28 of 87	180	NCT00261833	Trial comparisons
Tetomilast 25 mg vs Placebo: serious adverse events	13 of 51	12 of 33	84	NCT00874497	Trial comparisons
Prolastin (60 mg/kg Body Weight) vs Placebo: serious adverse events	9 of 38	15 of 39	77	NCT00263887	Trial comparisons
MMF - Cystic Fibrosis vs MMF - COPD, Emphysema, IPF, or A1AD: serious adverse events	13 of 33	14 of 35	68	NCT01014442	Trial comparisons
Alvelestat (MPH966) vs Placebo: Numbers and % of Subjects Who Experience at Least 1 Treatment-emergent Adverse Event	25 of 32	23 of 31	63	NCT03679598	Trial comparisons
Alvelestat (MPH966) vs Placebo: deaths from any cause	0 of 32	0 of 31	63	NCT03679598	Trial comparisons
Alvelestat (MPH966) vs Placebo: serious adverse events	0 of 32	0 of 31	63	NCT03679598	Trial comparisons
Cohort I: GLASSIA (High-end) vs Cohort II: GLASSIA (Low-end): Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution	0 of 18	0 of 16	34	NCT02525861	Trial comparisons
Cohort I: GLASSIA (High-end) vs Cohort II: GLASSIA (Low-end): Number of Participants With Treatment-Emergent Adverse Events (TEAEs)	13 of 18	9 of 16	34	NCT02525861	Trial comparisons
Cohort I: GLASSIA (High-end) vs Cohort II: GLASSIA (Low-end): Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 24 Hours Following the End of IP Infusion	7 of 18	3 of 16	34	NCT02525861	Trial comparisons

1 to 10 of 21

See all 21 comparisons in its trials

Papers from its trials20

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31467115	RESULT	1	PubMed
19483042	RESULT	1	PubMed
19251783	RESULT	1	PubMed
19196813	RESULT	1	PubMed
17290043	RESULT	1	PubMed
42852919	DERIVED	2	PubMed
37665565	DERIVED	1	PubMed
35948844	DERIVED	1	PubMed
30237305	DERIVED	2	PubMed
27916480	DERIVED	1	PubMed

1 to 10 of 20

See all 20 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004849

GET https://conductscience.org/api/diseases/v1/MONDO_0004849/drugs?page=2

API reference For AI assistants